Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORAL-Lung: Durvalumab, Tremelimumab, and Radiotherapy for NSCLC
NCT05000710Phase 2Active, not recruiting
- Sponsor
- Sheba Medical Center
- Start
- Dec 2021
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab and tremelimumab in non-small cell lung cancer (NSCLC), sponsored by Sheba Medical Center. Primary endpoint: treatment-related toxicity leading to treatment discontinuation at 2 years. Started Dec 2021; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05000710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05000710.